FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983258831> ?p ?o ?g. }

• W2983258831 endingPage "2116" @default.
• W2983258831 startingPage "2116" @default.
• W2983258831 abstract "Background Interventions for venous thromboembolism (VTE) prophylaxis and primary antimicrobial prophylaxis for chemotherapy-induced neutropenia and hematopoietic stem cell transplant (HSCT) recipients have resulted in reduced rates of VTE and infection. Appropriate prevention of thrombosis and infection requires a day-to-day evaluation in hospitalized hematology patients experiencing changing chemotherapy regimens and fluctuating neutrophil or platelet counts. Inappropriate use of anticoagulants in patients with thrombocytopenia may result in iatrogenic bleeding. Methods To evaluate appropriate antimicrobial and anticoagulant prophylaxis, a retrospective extraction of electronic medical records of hematology inpatients meeting eligibility criteria from 06/2017 - 06/2018 was completed. Appropriate use was determined by the University of Vermont Medical Center's internal protocols, which are derived from the current standard of care. Anti-viral prophylaxis (AVP) is required for any hospital day for patients undergoing HSCT and was within 180 days of transplant, or having a diagnosis of acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL), while on induction, consolidation, or maintenance chemotherapy, or was receiving specific therapy (e.g., Hyper-CVAD, CODOX-M, R-DA-EPOCH, VD-PACE, bendamustine, alemtuzumab (stopping when CD4 count >200), proteosome inhibitors, or Daratumumab). Anti-pneumocystis prophylaxis (APP) is required for any hospital day for patients diagnosed with ALL (on induction, consolidation, or maintenance chemotherapy, or therapies listed above), receiving high dose steroids (prednisone >20 mg/day or dexamethasone >4 mg/day for 30 or more days), purine analogs (e.g., fludarabine, clofarabine) or undergoing HSCT (after platelet engraftment). Antimicrobial prophylaxis was considered inappropriate when the above conditions were met but the patient was not provided the appropriate therapy during an inpatient day and did not have a documented contraindication. Anticoagulant prophylaxis (ACP) was considered inappropriate when an anticoagulant was provided on a hospital day when platelets were less than 50 K/cmm. Days where the patient missed a dose at admission or discharge were excluded. Results We evaluated a total of 221 patient visit records comprised of 142 unique patients. In total, on 189 (10.9%) of 1,734 total inpatient days evaluated, appropriate antimicrobial prophylaxis was not provided (Table 1). Regarding AVP, 15 (6.8%) patients missed at least one day, a total of 69 (4.0%) days. 11 (5.0%) patients missed at least one day of APP, a total of 120 (6.9%) days. Regarding ACP, there are 1,961 platelet count observations which included 219 visits from 140 unique patients (Table 2). Of these observations, 603 (30.8%) had platelet counts below 50 K/cmm. ACP was not held 18 times (3.0%) when platelet levels fell below 50 K/cmm. 51 patients (36.4%) had their platelets drop below 50 K/cmm at some point during their visit(s) of which 7 (13.7%) did not have ACP withheld. Conclusions and Discussion The results identify areas of improvement regarding antimicrobial prophylaxis. Antimicrobial prophylaxis is often not systematically evaluated on inpatient services and as such may not be consistently evaluated by clinicians rotating on the hematology service. Conversely, guidelines for withholding anticoagulant prophylaxis were more closely followed. This is likely due to the focus in recent years on anticoagulation prophylaxis and the near universal knowledge of bleeding risk when provided at low platelet levels. Inappropriate antithrombotic prophylaxis was most frequently noted at platelets of just below 50 K/cmm (i.e., 47-49 K/cmm) and immediately discontinued for following doses as platelet values declined. A potential intervention is the use of a daily checklist that can evaluate the use of these therapies. Disclosures No relevant conflicts of interest to declare." @default.
• W2983258831 created "2019-11-22" @default.
• W2983258831 creator A5018537967 @default.
• W2983258831 creator A5031870209 @default.
• W2983258831 creator A5081134934 @default.
• W2983258831 date "2019-11-13" @default.
• W2983258831 modified "2023-09-30" @default.
• W2983258831 title "Retrospective Review of Appropriate Use of Antimicrobials and Anticoagulants in Patients Hospitalized for a Malignant Hematologic Condition" @default.
• W2983258831 doi "https://doi.org/10.1182/blood-2019-121534" @default.
• W2983258831 hasPublicationYear "2019" @default.
• W2983258831 type Work @default.
• W2983258831 sameAs 2983258831 @default.
• W2983258831 citedByCount "0" @default.
• W2983258831 crossrefType "journal-article" @default.
• W2983258831 hasAuthorship W2983258831A5018537967 @default.
• W2983258831 hasAuthorship W2983258831A5031870209 @default.
• W2983258831 hasAuthorship W2983258831A5081134934 @default.
• W2983258831 hasConcept C126322002 @default.
• W2983258831 hasConcept C141071460 @default.
• W2983258831 hasConcept C194409129 @default.
• W2983258831 hasConcept C2776611710 @default.
• W2983258831 hasConcept C2776694085 @default.
• W2983258831 hasConcept C2777063308 @default.
• W2983258831 hasConcept C2777408962 @default.
• W2983258831 hasConcept C2778336483 @default.
• W2983258831 hasConcept C2778850193 @default.
• W2983258831 hasConcept C2779015954 @default.
• W2983258831 hasConcept C2911091166 @default.
• W2983258831 hasConcept C71924100 @default.
• W2983258831 hasConceptScore W2983258831C126322002 @default.
• W2983258831 hasConceptScore W2983258831C141071460 @default.
• W2983258831 hasConceptScore W2983258831C194409129 @default.
• W2983258831 hasConceptScore W2983258831C2776611710 @default.
• W2983258831 hasConceptScore W2983258831C2776694085 @default.
• W2983258831 hasConceptScore W2983258831C2777063308 @default.
• W2983258831 hasConceptScore W2983258831C2777408962 @default.
• W2983258831 hasConceptScore W2983258831C2778336483 @default.
• W2983258831 hasConceptScore W2983258831C2778850193 @default.
• W2983258831 hasConceptScore W2983258831C2779015954 @default.
• W2983258831 hasConceptScore W2983258831C2911091166 @default.
• W2983258831 hasConceptScore W2983258831C71924100 @default.
• W2983258831 hasIssue "Supplement_1" @default.
• W2983258831 hasLocation W29832588311 @default.
• W2983258831 hasOpenAccess W2983258831 @default.
• W2983258831 hasPrimaryLocation W29832588311 @default.
• W2983258831 hasRelatedWork W136411592 @default.
• W2983258831 hasRelatedWork W2016406397 @default.
• W2983258831 hasRelatedWork W2018507611 @default.
• W2983258831 hasRelatedWork W2034542762 @default.
• W2983258831 hasRelatedWork W2079537706 @default.
• W2983258831 hasRelatedWork W2096138651 @default.
• W2983258831 hasRelatedWork W2520789142 @default.
• W2983258831 hasRelatedWork W2584678776 @default.
• W2983258831 hasRelatedWork W2949664805 @default.
• W2983258831 hasRelatedWork W4317684538 @default.
• W2983258831 hasVolume "134" @default.
• W2983258831 isParatext "false" @default.
• W2983258831 isRetracted "false" @default.
• W2983258831 magId "2983258831" @default.
• W2983258831 workType "article" @default.